STIM
New Wall Street hype, same old ticker
Neuronetics got a fresh coat of bullish paint on Monday after BTIG initiated coverage with a Buy rating and a $5 price target. The stock jumped more than 28%, because apparently nothing wakes up a sleepy ticker quite like an analyst saying, “Hey, this could actually work.”
Why the market cared
This isn’t just a simple “analyst likes stock” moment. BTIG framed Neuronetics as a company entering a new phase, where its mental health platform and psilocybin exposure matter more than the old-school medical device label.
A few things are doing the heavy lifting here:
- The 2024 Greenbrook acquisition gave Neuronetics a broader mental health toolkit
- The company’s SPRAVATO program is helping boost sales
- BTIG sees upside from the market’s growing interest in psychedelic therapies
The Compass angle
Compass Pathways popped into the story too, since Neuronetics already has a collaboration agreement with CMPS. Compass recently said its COMP360 psilocybin therapy hit the primary endpoint in both Phase 3 trials, which keeps the whole psychedelic-therapy theme sizzling.
That said, CMPS is more sidekick than star here. The real headline is that BTIG thinks Neuronetics has become a more interesting hybrid: part treatment platform, part future optionality play.
Big picture
Neuronetics still has execution and reimbursement risk hanging around like a wet coat at the door. But when a stock is up double digits because analysts suddenly see a clearer path forward, investors tend to pay attention. The market loves a comeback story — especially one with a little biotech-flavored spice.